- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
The pharmaceutical sector originated in Europe. The biggest and most significant pharmaceutical markets are still in Europe and the United States. The majority of R&D investments are made by their enterprises, which remain major players on the international stage.
An organisation of the European Union (EU), the European Medicines Agency (EMA), is in charge of monitoring and evaluating pharmaceuticals.With funding from the European Union, the pharmaceutical industry, and indirect support from member states, the EMA was established with the declared goal of harmonising the activities of existing national medicine regulatory agencies.
It was hoped that this plan would eliminate the protectionist tendencies of sovereign states unwilling to approve new drugs that might compete with those already produced by domestic drug companies in addition to reducing the annual costs that drug companies incurred by having to obtain separate approvals from each member state.
The Europe pharmaceuticals marketaccounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Building on the work of the Innovative Medicines Initiative, the Innovative Health Initiative is a public-private joint venture that seeks to strengthen cooperation between the European Pharmaceutical and Related Industries and the European Commission.
The Innovative Medicines Initiative (IMI), which showed the value of a cooperative PPP model between the European Pharmaceutical Industry and the EC, is directly related to the Innovative Health Initiative (IHI).
Other industries have joined the PPP in addition to the European Pharmaceutical Industry's ongoing participation (through EFPIA), with the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry (COCIR), Medtech Europe, EuropaBio, and Vaccines Europe being the most notable.
As a result, the programme will be able to benefit from the ongoing technological convergence that integrates the digital, diagnostics, imaging, pharmaceutical, and biotech industries. More importantly, this would hasten innovation throughout the entire gamut of healthcare activities, from illness prevention and early diagnosis to treatment and care.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.